HER-2/neu status: A neglected marker of prognostication and management of breast cancer patients in India

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 4, 2013, Pages 2231-2235

  Zubeda, Syeda ^a,b   Kaipa, Prabhakar Rao ^b   Shaik, Noor Ahmad ^c   Mohiuddin, Mohammed Khaliq ^a   Vaidya, Sireesha ^a   Pavani, Boddana ^d   Srinivasulu, Mukta ^e   Latha, Manolla Madhavi ^a   Hasan, Qurratulain ^a,d  

^a Vasavi Medical and Research Centre   (India)

^b OSMANIA UNIVERSITY   (India)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d KAMINENI HOSPITALS   (India)

^e Mehdi Nawaz Jung Institute of Oncology   (India)

Author keywords

Breast cancer; Developing countries; ER; HER 2; India; PR; Receptor status

Indexed keywords

EID: 84880321379     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.4.2231     Document Type: Article

References (34)

1. Al-Ahwal MS (2006). HER-2 positivity and correlations with other histopathologic features in breast cancer patients hospital based study. J Pak Med Assoc, 56, 65-8.
2. Almasri NM, Al Hamad M, (2005). Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res, 7, 598-604.
3. Ambroise M, Ghosh M, Mallikarjuna VS, Kurtian A (2011). Immuno histochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev, 12, 625-9.
4. Ariga R, Zarif A, Korasick J, et al (2005). Correlation of her-2/ neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast, 11, 278-80.
5. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD (1996). Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer, 74, 1445-51.
6. Desai SB, Moonim MT, Gill AK, et al (2000). Hormone receptor status of breast cancer in India: a study of 798 tumours. Breast, 9, 267-70.
7. Dutta SM CV, Chopra SM BGS, Sahai Lt CK, Nema B SK, (2008). Hormone receptors, Her-2/Neu and chromosomal aberrations in breast cancer. MJAFI, 64, 11-5.
8. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
9. Francis GD, Dimech M, Giles L, Hopkins A (2007). Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA quality assurance program. J Clin Pathol, 60, 1277-83.
10. Higgins MJ, Baselga J (2011). Targeted therapies for breast cancer. J Clin Invest, 121, 3797-803.
11. Huang HJ, Neven P, Drijkoningen M, et al (2005). Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol, 58, 611-6.
12. Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M (2007). Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors ininvasive ductal breast cancer. In Vivo, 21, 673-8.
13. Kamil M, Yusuf N, Khalid I, et al (2010). Association between HER-2/neu over-expression and clinico-pathologic parametersof breast cancer in northern Malaysia. Ceylon Med J, 55, 9-13.
14. Kraft P, Haiman CA (2010). GWAS identifies a common breast cancer risk allele among BRCA1 carriers. Nat Genet, 42, 819-20.
15. Kumar V, Abbas AK, Fausto N, Aster J (2010). Robbins and cotran pathologic basis of disease, 8th edn. 1119-54, USA, Elsevier.
16. Kumar V, Tewari M, Singh U, Shukla HS (2007). Significance of Her-2/neu protein over expression in Indian breast cancer patients. Indian J Surg, 69, 122-8.
17. Lal P, Tan LK, Chen B (2005). Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol, 123, 541-6.
18. Liu Y, El-Ashry D, Chen D, Ding IY, Kern FG (1995). MCF-7 breast cancer cells over expressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifin-sensitivity in vivo. Breast Cancer Res Treat, 34, 97-117.
19. Livi L, Meattini I, Saieva C, et al (2011). Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. Cancer, 118, 3236-43.
20. Lovekin C, Ellis IO, Locker A, et al (1991). c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer, 63, 439-43.
21. Lu M, Whelan SA, He J, et al (2010). Hydrophobic proteome analysis of triple negative and hormone receptor Her2 negative breast cancer by mass spectrometer. Clin Proteomics, 3, 93-103
22. Marsiglinate S, Muscella A, Ciardo V, et al (1993). Enzymelinked immunosorbent assay of HER-/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsins D and histologic grades. Cancer Lett, 75, 195-206.
23. Masood S (2010). The current status of breast cancer among resource-limited countries. Middle East J Cancer, 1, 1-4.
24. Massarweh S, Schiff R (2007). Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res, 13, 1950-4.
25. Misrahi M, Atger M, D'Auriol L, et al (1987). Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA. Biochem Biophys Res Commun, 143, 740-8.
26. Munjal K, Ambaye A, Evans MF, et al (2009). Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients. Asian Pac J Cancer Prev, 10, 773-89.
27. Naeem M, Nasir A, Aman Z, Ahmad T, Samad A (2008). Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer. J Ayub Med Coll Abbottabad, 20, 23-6.
28. Oh AS, Lorant LA, Holloway JN, et al (2001). Hyperactivation of MAPK induces loss of ER alpha expression in breast cancer cells. Mol Endocrinol, 15, 1344-59.
29. Patil VW, Singhai R, Patil A V, Gurav (2011). PD Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women. Breast Cancer: Targets and Therapy, 3, 9-19.
30. Ratnatunga N, Liyanapathirana LV (2007). Hormone receptor expression and Her/2neu amplification in breast carcinoma in a cohort of Sri Lankans. Ceylon Med J, 52, 133-6.
31. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD (2000). Frequency of oestrogen and progesterone receptor positive by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol, 53, 688-96.
32. Shyamala G, Yang X, Cardiff RD, Dale E (2000). Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc Natl Acad Sci USA, 97, 3044-9.
33. Taucher S, Rudas M, Mader RM, et al (2003). Do we need HER- 2/neu testing for all patients with primary breast carcinoma?. Cancer, 198, 2547-53.
34. Vaidyanathan K, Kumar P, Reddy CO, et al (2010). ErbB- 2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Cancer, 47, 8-15.